TapImmune Provides First Quarter 2017 Corporate and Clinical Update
TAPIMMUNE INC COMMON (TPIV)
NASDAQ:AMEX Investor Relations:
tapimmune.com/investors
Company Research
Source: PR Newswire
JACKSONVILLE, Fla., May 31, 2017 /PRNewswire/ -- Recent Corporate and Clinical Developments:Appointed Dr. Richard Kenney as Head of Clinical Development Continued advancing multiple Phase 2 clinical studies of lead vaccine candidate TPIV 200 in ovarian and triple-negative breast cancers Progressed preclinical development of proprietary PolyStart™ vaccine expression technologyAnticipated 2017 Milestones:2Q 2017: On track to achieve 50% enrollment in ongoing Phase 2 dosing study of TPIV 200 for treating triple-negative breast cancer (TNBC) 3Q 2017: Publish long-term safety, immune response and survival data from completed Phase 1 clinical study of TPIV 200 3Q 2017: Report interim results from ongoing Phase 2 study of TPIV 200 in combination with AstraZeneca's durvalumab in patients with platinum-resistant ovarian cancer 3Q 2017: Mayo Clinic to initiate 280-patient Phase 2 study of TPIV 200 in women with advanced triple-negative breast cancer 4Q 2017: On track to complete enrollment in P
Show less
Read more
Impact Snapshot
Event Time:
TPIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TPIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TPIV alerts
High impacting TAPIMMUNE INC COMMON news events
Weekly update
A roundup of the hottest topics